sulfisoxazole · Roche · NDA 006525, 006917, 007757, 008414, 009182
Gantrisin
Earliest generic entry, as listed · earliest of 5 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 006525 · 001 · discontinued | tablet, oral | 500MG | open |
| 006917 · 001 · discontinued | injectable, injection | EQ 400MG BASE/ML | open |
| 007757 · 002 · discontinued | solution/drops, ophthalmic | EQ 4% BASE | open |
| 008414 · 002 · discontinued | ointment, ophthalmic | EQ 4% BASE | open |
| 009182 · 002 · discontinued | syrup, oral | EQ 500MG BASE/5ML | open |